About one-quarter of the pulmonary arterial hypertension (PAH) patients in a small study showed cognitive deficits, typically mild impairments in executive function and memory. Problems in abilities like executive function — a set of skills that include thinking, self control, and readily accessible memory that’s part of everyday life…
News
Inhaled nitric oxide (iNO) therapy reduces the risk of death in preterm infants with severe hypoxemic respiratory failure (HRF) — low oxygen in the blood — and suspected or confirmed pulmonary hypertension (PH), a study shows. “The findings provide evidence supporting the prognostic value of oxygenation response and support…
The risk of mortality is nine times greater for people who have signs of pulmonary hypertension (PH) on an echocardiogram when they get COVID-19, than people without these signs, a study finds. The study, “Pulmonary hypertension predicts higher mortality in patients admitted with severe COVID-19 infection,” was published…
Certain proteins implicated in the immune response and inflammation showed a potential to serve as blood biomarkers of pulmonary arterial hypertension (PAH) in a recent study. A possible diagnostic biomarker was seen in the TNF‐related apoptosis‐inducing ligand (TRAIL) protein. It demonstrated an ability to distinguish PAH patients not only…
Scientists in India have developed derivatives of bosentan — the active ingredient in Tracleer — that were able to ease signs of pulmonary arterial hypertension (PAH) in a rat model. In addition to lowering blood pressure and restoring more normal heart and lung architecture, the molecules lowered biomarkers…
Roughly one in four people with idiopathic (of unknown cause) pulmonary arterial hypertension (PAH) also have diabetes, a disease that causes high blood glucose (sugar), a multi-center Polish study found. Having diabetes was linked to more advanced pulmonary vascular disease and worse survival, which held true even after accounting…
Switching to Orenitram, an oral formulation of treprostinil, appears safe and may benefit some patients with pulmonary arterial hypertension (PAH) who are not responding well to Uptravi (selexipag) or are experiencing side effects from such treatment. That’s according to data from a small group of 10 patients who…
Older age and high blood pressure in the pulmonary arteries raise the risk of complications with balloon pulmonary angioplasty (BPA), a second-line treatment for chronic thromboembolic pulmonary hypertension (CTEPH), a study suggested. If high blood pressure persists after surgery to remove the pulmonary arterial blood clots that cause…
Liquidia is seeking to extend the tentative approval of Yutrepia, an inhaled dry powder formulation of treprostinil for pulmonary arterial hypertension (PAH), to include pulmonary hypertension associated with interstitial lung disease (PH-ILD). PH-ILD occurs when blood pressure in the lungs is high due to a disease that causes lung…
Keros Therapeutics has announced that it will launch a Phase 2 trial to assess the effectiveness of KER-012 as an add-on treatment for patients with pulmonary arterial hypertension (PAH). This follows the recent clearance by the U.S. Food and Drug Administration (FDA) of an investigational new drug (IND)…
People with a combination of two lung diseases — specifically pulmonary fibrosis and emphysema, known as CPFE — who also have pulmonary hypertension (PH) were found to be at an increased risk of death in comparison to CPFE patients without PH, according to a new meta-analysis. Having CPFE also…
Tenax Therapeutics has been issued a U.S. patent covering oral levosimendan, also known as TNX-103, for the treatment of pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). The patent (U.S. Patent No. 11,701,355) is expected to provide intellectual property protection for TNX-103 through December 2040.
